You're describing a complex organic molecule with a long, technical name. Let's break down its structure and why it might be important for research.
**The Structure**
* **1-(2-furanyl)-:** This indicates a furanyl (a five-membered ring containing oxygen) group is attached at the 1-position of another structure.
* **N-[[1-[(4-methylphenyl)sulfonylmethyl]-5-tetrazolyl]methyl]-:** This is a complex side chain with multiple functional groups:
* **Tetrazole:** A five-membered ring containing four nitrogen atoms.
* **Sulfonylmethyl:** A sulfur group with two oxygen atoms (sulfonyl) attached to a methylene group (CH2).
* **Methylphenyl (4-methylphenyl):** A benzene ring with a methyl group attached at the 4-position.
* **N-(thiophen-2-ylmethyl):** This is another side chain containing:
* **Thiophen:** A five-membered ring containing sulfur.
* **Methyl (methyl):** A single carbon atom (CH3).
**Possible Research Significance**
Given the structure, this compound likely belongs to a class of molecules with interesting biological activity. Here's why:
* **Potential as a Drug Candidate:** The presence of heterocyclic rings (furan, thiophen, tetrazole) and various functional groups often points to compounds that can interact with biological systems.
* **Drug Targets:** The specific arrangement of these groups could allow the molecule to bind to specific proteins or receptors in the body, potentially modulating their function.
* **Pharmacological Research:** This compound could be used in pharmacological research to:
* **Identify New Drug Targets:** Testing its effects on cells and tissues might reveal new biological pathways or targets for drug development.
* **Improve Existing Drugs:** The molecule could be a starting point for designing new drugs that are more potent, have fewer side effects, or can be delivered more effectively.
* **Materials Science:** The chemical properties of this compound (its ability to interact with other molecules) could also be relevant for materials science applications.
**To Find Out More**
To get a more precise understanding of the research importance of this specific compound, you would need more information:
* **Source:** Where did you find this compound name? Is it from a research paper, a patent, or a chemical database?
* **Context:** What was the research focusing on? Was it related to a specific disease or biological process?
By searching online databases or scientific literature using the compound's name or a similar chemical structure, you can likely find information about its research significance.
ID Source | ID |
---|---|
PubMed CID | 644648 |
CHEMBL ID | 1360272 |
CHEBI ID | 121402 |
Synonym |
---|
HMS1693L03 |
furan-2-ylmethyl-thiophen-2-ylmethyl-[1-(toluene-4-sulfonylmethyl)-1h-tetrazol-5-ylmethyl]-amine |
smr000004014 |
MLS000030355 , |
MLS001385335 |
CHEBI:121402 |
1-(furan-2-yl)-n-[[1-[(4-methylphenyl)sulfonylmethyl]tetrazol-5-yl]methyl]-n-(thiophen-2-ylmethyl)methanamine |
AKOS000795427 |
HMS2174P22 |
CHEMBL1360272 |
Q27209942 |
1-(2-furanyl)-n-[[1-[(4-methylphenyl)sulfonylmethyl]-5-tetrazolyl]methyl]-n-(thiophen-2-ylmethyl)methanamine |
Class | Description |
---|---|
sulfonic acid derivative | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
glp-1 receptor, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
TDP1 protein | Homo sapiens (human) | Potency | 11.5821 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 44.6684 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 25.1189 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 19.9526 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 12.5893 | 0.6561 | 9.4520 | 25.1189 | AID927 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 14.1254 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 12.5893 | 1.5849 | 13.0043 | 25.1189 | AID927 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |